NCT00332904

Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis

Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Hvidovre University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study´s purpose is to investigate the effect of beta blockade or aldosterone antagonist therapy on oxygenation, peripheral and cardiac hemodynamics and humoral systems, in patients with liver cirrhosis.

Detailed description

Cardio-pulmonal complications to patients with liver cirrhosis and portal hypertension determine the patients' prognosis. Most patients have hemodynamical changes in circulation with increased cardiac output and decreased systolic function in stress. Endothelial dysfunction is a parameter for bad prognosis in cardiovascular disease. The Renin-angiotensin-aldosterone-system plays an important role in natrium and volume regulation. Descriptions of changes in the peripheral circulation and oxygenation have been deficient up to now. Patients with liver cirrhosis and portal hypertension are betablockers and/or aldosterone antagonists routine treatment - effects on peripheral hemodynamics and oxygenation in relation to central hemodynamic changes are deficient.

Conditions

• Liver Cirrhosis
• Portal Hypertension

Interventions

Type	Name	Description
DRUG	propranolol	tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
DRUG	spironolactone	tablet 200 mg pr. day in 3 weeks, evt. dose adjustment

Timeline

• Start date: 2006-08-01
• Primary completion: 2008-07-01
• Completion: 2010-12-01
• First posted: 2006-06-02
• Last updated: 2010-06-04

Locations

1 site across 1 country: Denmark